Human Papillomavirus Bivalent (Types 16 and 18) Vaccine, Recombinant (Cervarix)

Elliott, William T.; Chan, James
December 2009
Internal Medicine Alert;12/29/2009, Vol. 31 Issue 24, p190
Product Review
The article evaluates Cervarix, a human papillomavirus (HPV) bivalent and recombinant vaccine for Types 16 and 18 from GlaxoSmithKline.


Related Articles

  • Global Advisory Committee on Vaccine Safety, 17--18 December 2008.  // Weekly Epidemiological Record;1/30/2009, Vol. 84 Issue 5, p37 

    Information on several topics discussed at the 19th meeting of Global Advisory Committee on Vaccine Safety (GACVS) in Geneva, Switzerland on December 17 to 18, 2008 is presented. Discussions include the studies that evaluate the safety of Rotateq and Rotarix vaccines, post-marketing information...

  • CERVARIX.  // Physician Assistants' Prescribing Reference;Spring2010, Vol. 17 Issue 1, pA9 

    The article evaluates the Cervarix pappillomavirus vaccine from GlaxoSmithKline.

  • UK Chooses GSK Vaccine. Houlton, Sarah // Pharmaceutical Executive;Aug2008, Vol. 29 Issue 8, p18 

    The article reports on the selection of GlaxoSmithKline's Cervarix for British human papillomavirus vaccine immunization program in Great Britain. It is noted that in September 2008, the program will vaccinate 12- and 13-year-old girls. British Health Minister Dawn Primarolo believes that the...

  • IN BRIEF.  // BMJ: British Medical Journal (Overseas & Retired Doctors Edition;10/3/2009, Vol. 339 Issue 7724, p774 

    This section offers world news briefs. Coventry Teaching Primary Care Trust in England set an inquiry after the death of Natalie Morton, a 14-year-old girl who had given a vaccination against the human papillomavirus at school. A tropical storm that hit the Philippines on September 26, 2009...

  • Human papillomavirus (HPV) vaccines. Visser, Adele; Hoosen, Anwar // CME: Continuing Medical Education;Jan2012, Vol. 30 Issue 1, p29 

    The article describes the two prophylactic human papillomavirus (HPV) vaccines that are commercial available. These are the bivalent vaccine Cervarix from GlaxoSmithkline Biologicals and the quadrivalent vaccine Gardasil from Merck and Co. The article cites studies which show the efficacy of...

  • GSK and Merck to provide cheap cancer vaccine.  // TCE: The Chemical Engineer;Jun2013, Issue 864, p16 

    The article discusses a deal between health care companies GlaxoSmithKline (GSK) and Merck to provide cut-price human papillomavirus (HPV) vaccines for use in poor countries. The two companies have partnered with the GAVI Alliance, which is composed of governments, drug companies, and...

  • Update on the Status of HPV Vaccines.  // Immunization Newsletter;2007, Vol. 29 Issue 6, p1 

    The article focuses on human papillomavirus (HPV) vaccines and their efficacy. The vaccine helps in prevention of cervical cancer. Some of the HPV vaccines mentioned are Gardasil, a quadrivalent vaccine formulated by Merck & Co. Inc. and Cervarix, a bivalent vaccine by GlaxoSmithKline. The...

  • CERVARIX.  // Monthly Prescribing Reference;Dec2009, Vol. 25 Issue 12, pA10 

    The article offers information on Cervarix vaccine from GlaxoSmithKline. Cervarix has an active ingredient of bivalent human papillomavirus (HPV) vaccine types 16 and 18 vaccine. The drug is used to prevent cervical cancer and cervical intraepithelial neoplasia (CIN) grade 1 in females 10-25...

  • Vaccines. Pines, Noah // Medical Marketing & Media;Oct2013, Vol. 48 Issue 10, p70 

    The article focuses on the low vaccination rates among teenagers and adults, despite the efforts by public health officials and drug makers to educate the public. It says that pharmaceutical firms GlaxoSmithKline and Merck have urged human pappillomavirus (HPV) vaccination of teenagers. Martin...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics